---
slug: healthspan-t2d-risk-model-clinical-implementation-plan
status: draft
created: '2026-03-20'
updated: '2026-03-20'
version: 0.1.0
tags:
- multiplicity
traceability:
  path: 04-domains/healthcare/healthspan/Healthspan T2D Risk Model_ Clinical Implementation
    Plan.md
  last_synced: '2026-03-20T17:17:18.797249Z'
---

**Healthspan T2D Risk Model: Clinical Implementation Plan**
===========================================================

### **1.0 Introduction and Strategic Objective**

This document provides a comprehensive implementation plan detailing the
operational steps, governance structure, and quality assurance protocols
for deploying the Healthspan T2D Early-Risk Prediction Model into a live
clinical setting. The plan is designed to ensure a safe, effective, and
sustainable integration of the model into clinical workflows.

The strategic objective of this initiative is to leverage routine
Electronic Health Record (EHR) data to accurately predict the risk of
incident type 2 diabetes (T2D) at 1, 3, and 5-year horizons. By
identifying high-risk individuals earlier than current standard-of-care
practices, the model aims to enable timely and targeted interventions,
ultimately improving patient outcomes.

This plan is intended for the clinical and technical leadership teams
responsible for overseeing the model\'s deployment, ongoing management,
and governance. The following sections will provide a detailed overview
of the model\'s scope, the pre-deployment validation framework, and the
post-deployment monitoring and risk management protocols.

### **2.0 Model Overview and Scope**

A clear and shared understanding of the model\'s technical
specifications and intended clinical scope is foundational to a
successful deployment. This section defines the key characteristics of
the T2D risk model and the specific patient population it is designed to
evaluate.

-   **Model Type:** The model is a Transformer-based sequence classifier
    > that analyzes monthly slices of a patient\'s EHR data from up to
    > the last 24 months.

-   **Prediction Horizons:** The model generates three independent risk
    > scores for a patient developing T2D within the next **1, 3, and 5
    > years**.

-   **Primary Endpoint:** While all horizons are reported, the 3-year
    > risk prediction (H=3y) is designated as the primary metric for
    > evaluating the model\'s success and performance.

-   **Input Data:** The model exclusively uses structured EHR data. This
    > includes demographics, vitals, specific laboratory results (e.g.,
    > HbA1c, fasting glucose, lipid panel), records of specific
    > medication classes (e.g., antihypertensives, statins), and
    > utilization features.

The model is designed for a specific target patient cohort, defined by
the following criteria:

  Attribute                Specification
  ------------------------ ------------------------------------------------------------------------------------------------
  **Inclusion Criteria**   Adults aged 18--90 years with ≥ 3 encounters and ≥ 12 months of history before the index date.
  **Exclusion Criteria**   Any prior evidence of T2D before the index date.

With the model\'s design established, the following sections detail the
rigorous validation and governance framework required before and after
clinical deployment.

### **3.0 Pre-Deployment: Validation and Governance Framework**

The pre-deployment phase is a critical period for ensuring the model is
accurate, fair, and technically prepared for clinical application. The
following steps constitute the formal quality gates that the model must
pass before it can be approved for go-live, guaranteeing that it meets
the highest standards of safety and efficacy.

#### **3.1 Data Governance and Lineage**

A robust data governance protocol is essential for ensuring the model\'s
integrity and reproducibility. All data handling and model training will
adhere to the following core principles:

1.  **Pre-registration:** The complete model development protocol will
    > be formally documented and registered prior to execution to ensure
    > transparency and prevent post-hoc modifications.

2.  **Containerized Training:** The training environment will be
    > encapsulated in a software container with deterministic seeds.
    > This guarantees that the model training process is fully
    > replicable.

3.  **Data Versioning:** A clear and auditable lineage will be
    > maintained for all data extraction and processing steps, ensuring
    > traceability from raw data to model input.

4.  **Data Security:** Protected Health Information (PHI) will not leave
    > the local site. Any multi-site collaboration will be conducted via
    > federated aggregation methods to preserve data privacy and
    > security.

#### **3.2 Formal Acceptance Criteria**

Before clinical deployment, the model must pass a final \"Acceptance
Gate\" by meeting a series of non-negotiable performance criteria on a
held-out test dataset. These criteria ensure the model provides a
tangible and reliable clinical benefit.

-   **Superior Predictive Performance:** The model must demonstrate a
    > statistically significant improvement over the XGBoost baseline,
    > defined as an increase in the Area Under the Receiver Operating
    > Characteristic Curve (ΔAUROC) of ≥ 0.02 for the primary 3-year
    > prediction horizon. This criterion confirms that the advanced
    > Transformer model offers a clinically meaningful improvement in
    > predictive power over a strong, established baseline, justifying
    > its implementation.

-   **Excellent Calibration:** The model\'s risk predictions must be
    > reliable and accurately reflect the true probability of outcomes,
    > validated by achieving an Expected Calibration Error (ECE) of ≤
    > 0.03. This ensures clinicians can trust the model\'s output; for
    > instance, a predicted 20% risk should correspond to an actual
    > event rate of approximately 20% in that patient group.

-   **Demonstrated Clinical Utility:** The model must show a positive
    > net benefit as measured by decision-curve analysis at a clinically
    > determined risk threshold (τ). This confirms that using the model
    > to guide clinical decisions would be more beneficial than the
    > default strategies of intervening on all patients or no patients.

-   **Multi-Horizon Integrity:** The secondary 1-year and 5-year
    > prediction horizons must show no clinically material performance
    > degradation. This ensures that while the 3-year horizon is
    > primary, the other risk predictions are also sound and do not
    > introduce clinical confusion or risk.

-   **Clinical Rule Effectiveness:** A \"Risk Persistence Rule,\" which
    > defines high risk as ≥2 alerts within ≤6 months, must improve the
    > Positive Predictive Value (PPV) with a relative sensitivity loss
    > of no more than 25% compared to a single-encounter alert rule.
    > This validates that a more conservative alerting strategy
    > effectively reduces false alarms and physician alert fatigue
    > without missing an unacceptable number of true T2D cases.

Upon satisfying all acceptance criteria, the model can proceed to a
controlled clinical launch, supported by the continuous monitoring plan
outlined next.

### **4.0 Post-Deployment: Monitoring and Risk Management**

Model deployment is the beginning of an ongoing lifecycle, not the end
of a project. This section defines the continuous monitoring,
governance, and risk mitigation strategies essential for maintaining
patient safety, model efficacy, and clinical trust over time.

#### **4.1 Ongoing Performance Monitoring Protocol**

An automated monitoring system will be implemented to track model
performance and data stability in the live clinical environment. The
system will operate based on pre-defined triggers that, if crossed, will
prompt specific actions to ensure the model remains safe and effective.

  Metric / Condition                    Trigger Threshold                                                        Required Action
  ------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------
  **Calibration Drift**                 ECE \> 0.05 for two consecutive quarters.                                Initiate model recalibration.
  **Predictive Power Degradation**      AUROC drop ≥ 0.03 for two consecutive quarters.                          Initiate model recalibration.
  **Statistical Calibration Failure**   Spiegelhalter's z-test p \< 0.01.                                        Initiate model recalibration.
  **Population Shift**                  Population Stability Index (PSI) \> 0.2 on any of the top-10 features.   Investigate feature drift; may trigger recalibration.

#### **4.2 Risk Mitigation and Escalation Pathway**

A proactive risk management plan has been established to address
potential challenges that may arise post-deployment. The following
pathways define the mitigation strategies for key identified risks.

-   **Model Performance Degradation:** If an automated monitoring
    > trigger is activated, the first action is to recalibrate the model
    > on the most recent 12 months of data. If recalibration fails to
    > resolve the issue, a full model retraining will be initiated. If
    > performance remains degraded after retraining, the model will be
    > rolled back from clinical use pending further investigation.

-   **Label Noise:** The risk of inaccurate T2D labels in the training
    > data is mitigated by using strict endpoint definitions (e.g.,
    > requiring confirmatory lab values or multiple ICD codes) and
    > conducting sensitivity analysis to assess the model\'s robustness.

-   **Selection Bias:** To ensure the model is applied to the
    > appropriate population, a patient flow diagram will be maintained,
    > and the characteristics of the patient cohort included in the
    > model will be continuously compared against those who are
    > excluded.

-   **Overfitting:** The model\'s tendency to perform well on training
    > data but poorly on new data is mitigated through rigorous
    > techniques during development, including comparison against strong
    > baseline models, ablation studies, and the use of early stopping.

-   **Data Quality Issues:** The risk of poor input data is managed
    > through systematic data plausibility checks (e.g., identifying
    > unrealistic vital sign values) and unit harmonization during data
    > preprocessing.

#### **4.3 Interpretability and Error Analysis**

To ensure model transparency and facilitate continuous improvement, a
formal protocol for interpretability and error analysis will be
implemented.

1.  **Clinical Interpretability:** Model predictions presented to
    > clinicians will be accompanied by feature attribution analysis to
    > provide context. This will be generated using SHAP for the XGBoost
    > baseline and Integrated Gradients for the Transformer model. A
    > clinical panel will conduct periodic face-validity reviews to
    > ensure the model\'s reasoning aligns with clinical knowledge.

2.  **Systematic Error Review:** On a regular basis, manual chart
    > reviews will be performed on at least 50 high-confidence false
    > positives and 50 false negatives. The objective is to categorize
    > the root causes of these errors (e.g., data gaps, atypical patient
    > physiology, label noise) and develop a remediation plan to improve
    > future model versions.

This comprehensive plan provides the framework necessary for a safe,
effective, and sustainable deployment of the Healthspan T2D risk model,
ensuring it remains a valuable tool in the proactive management of
patient health.
